NFE2L2 and Insulin resistance: In line, treatment with CDDO-methyl ester (CDDOMe), another NRF2 activator, decreases total body fat, plasma lipids levels, FFA levels and improves glucose tolerance and insulin resistance in HFD-fed mice.